全球疫苗技術市場

全球疫苗技術市場規模預計將從2023年的450億美元成長到年終的653億美元，預測期內複合年成長率為7.8%。

次單元、重組、多醣和結合疫苗行業預計將從 2023 年的 235 億美元成長到 2028 年的 344 億美元，同期複合年成長率為 7.9%。減毒疫苗產業預計也將從 2023 年的 84 億美元成長到 2028 年的 121 億美元，複合年成長率為 7.6%。

本報告調查了全球疫苗技術市場，包括市場和技術背景、市場影響因素分析、市場規模趨勢和預測、各個細分市場和地區的詳細分析、技術趨勢、競爭形勢和主要企業。， ETC。

目錄

第1章簡介

第 2 章摘要/亮點

• 市場展望
• 市場洞察

第3章市場與技術背景

• 定義
• 免疫系統和疫苗
• 免疫系統的組成部分
• 免疫系統的細胞
• 免疫反應
• 主要組織相容性複合體 (MHC)
• 疫苗接種及疫苗
• 免疫系統疾病
• 生活方式如何影響您的免疫系統
• 疫苗如何發揮作用
• 疫苗接種原則
• 免疫類型
• 疫苗接種的好處
• 疫苗的歷史
• 疫苗和免疫接種，概述
• 疫苗類型
• 減毒（活）疫苗
• 去活化（去活化）疫苗
• 類毒素疫苗
• 次單位疫苗
• 結合疫苗
• 重組載體疫苗
• DNA疫苗
• RNA疫苗
• 免疫
• 疫苗接種的優點
• 佐劑和賦形劑
• 病原體的成分
• 顆粒佐劑
• 可以透過疫苗預防的感染疾病
• 人類疾病
• 病毒性疾病
• 細菌性疾病
• 監管方面
• 世界衛生組織 (WHO) 認證的疫苗
• 新產品核准
• 記起
• 疫苗監管的重要進展

第4章市場動態

• 概述
• 市場促進因素
• 提高疫苗接種意識
• 擴大投資和研發
• 新疫苗
• 感染疾病流行
• 市場抑制因素
• 疫苗開發和定價
• 市場機會
• 新興市場需求增加
• 治療性疫苗

第5章 COVID-19 疫苗的全球市場

• 概述
• COVID-19 疫苗技術
• mRNA技術的出現
• COVID-19 對常規嬰兒免疫接種的影響
• 由於新冠肺炎 (COVID-19) 造成的中斷
• 全球覆蓋率停滯不前
• 按國家/地區分類的進展和挑戰

第6章市場細分：依技術分類

• 全球疫苗技術市場：依技術分類
• 次單元、重組、多醣體和結合疫苗
• 減毒活病毒疫苗
• 去活化疫苗
• 類毒素疫苗
• 其他/聯合疫苗

第7章市場細分：依疾病分類

• 全球疫苗技術市場：依疾病分類
• 肺炎球菌
• 白喉和破傷風
• HPV
• MMR
• 其他

第8章市場細分：依年齡段

• 全球疫苗技術市場：依年齡層分類
• 兒童
• 青少年/成人

第9章市場細分：依地區

• 全球疫苗技術市場：按地區分類
• 北美洲
• 歐洲
• 亞太地區
• 其他地區

第10章新技術和新進展

• 發育狀況
• mRNA疫苗
• 病毒載體疫苗
• 奈米顆粒疫苗
• DNA疫苗
• 類病毒顆粒（VLP）疫苗
• 自擴增RNA疫苗
• 創新佐劑
• 人工智慧/計算生物學
• 個體化疫苗
• 植物疫苗

第11章競爭形勢

• 競爭形勢
• 企業市場占有率分析

第12章 公司簡介

• ABBOTT
• ASTRAZENECA
• BAVARIAN NORDIC
• BHARAT BIOTECH INTERNATIONAL LTD.
• EMERGENT BIOSOLUTIONS INC.
• GSK PLC.
• JOHNSON & JOHNSON SERVICES INC.
• MERCK & CO. INC.
• MITSUBISHI TANABE PHARMA CORP.
• PANACEA BIOTEC LTD.
• PFIZER INC.
• SANOFI

第 13 章附錄：縮寫列表

Highlights:

The global market for vaccine technologies is expected to grow from $45.0 billion in 2023 to $65.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2028.

The global market for subunit, recombinant, polysaccharide, and conjugate vaccines is expected to grow from $23.5 billion in 2023 to $34.4 billion by 2028, at a CAGR of 7.9% from 2023 to 2028.

The global market for live-attenuated vaccines is expected to grow from $8.4 billion in 2023 to $12.1 billion by 2028, at a CAGR of 7.6% from 2023 to 2028.

Report Scope:

This report explains critical trends in the vaccine industry. It discusses the market determinants, which act as motivating or restraining factors and provides insights to stakeholders and potential entrants.

This report includes only human vaccines; animal vaccines have not been considered in this report.

This study looks at research and development (R&D) spending, increasing competition and new technologies, which are giving direction to the market. These advancements, new product launches and changing lifestyles are influencing future market growth.

Company mergers, acquisition strategies and collaborations are also covered in this report. Additionally, this study discusses the strengths and weaknesses of each strategy type, considering new technologies, growing competition and changing customer needs.

The market has been analyzed based on the application of current vaccines. Categories considered in this report include pneumococcal vaccines; diphtheria, tetanus vaccines; HPV vaccines; MMR vaccines; and other vaccines including rotavirus vaccines, influenza vaccines, hepatitis B vaccines, chickenpox vaccines, polio vaccines, BCG, and yellow fever vaccines.

This study details market growth among vaccine manufacturers and end users. Genomic research centers, academic institutions, government and private laboratories, various hospital settings, and pharmaceutical, diagnostic and biotechnology companies and physicians will find this study to be of interest.

This report provides useful information to all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this study useful.

Report Includes:

• 34 data tables and 63 additional tables
• An up-to-date overview of the global markets for vaccine technologies
• Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Estimate of the market size and revenue forecast for the global market, and a corresponding market share analysis based on technology, disease indication, age group and region
• Facts and figures pertaining to the market drivers, opportunities and challenges, emerging technologies, global R&D spending, and the regulatory landscape
• Assessment of present and future strategies in the innovation-driven vaccine technologies market, and a look at the vaccines for humans and their immunization schedule
• Discussion of the importance of ESG in the market for vaccine technologies, including consumer attitudes, the impact of ESG factors on company performance, and ESG practices of leading companies
• Review of patents and patent applications
• Overview of the major vendors, along with an analysis of the industry structure, including company market shares, recent M&A activity, and venture funding
• Analysis of the competitive landscape based on recent developments and segmental revenues
• Profiles of the leading companies

Table of Contents

Chapter 1 Introduction

• Study Background
• Study Goals and Objectives
• Reasons for Doing this Study
• Scope of Report
• What's New in This Update?
• Methodology
• Information Sources
• Geographic Breakdown
• Segmentation Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Insights

Chapter 3 Market and Technology Background

• Definitions
• Immune System and Vaccines
• Components of the Immune System
• Cells of the Immune System
• Immune Response
• Major Histocompatibility Complex (MHC)
• Immunization and Vaccines
• Disorders of the Immune System
• Impact of Lifestyle on the Immune System
• How Vaccines Work
• Principles of Immunization
• Types of Immunity
• Advantages of Vaccination
• History of Vaccines
• Vaccines and Immunization, Overview
• Types of Vaccines
• Attenuated (Live) Vaccines
• Inactivated (Killed) Vaccines
• Toxoid Vaccines
• Subunit Vaccines
• Conjugate Vaccines
• Recombinant Vector Vaccines
• DNA Vaccines
• RNA Vaccines
• Immunization
• Advantages of Immunization
• Adjuvants and Excipients
• Pathogen Components
• Particulate Adjuvants
• Infectious Diseases Preventable by Vaccine
• Human Diseases
• Viral Diseases
• Bacterial Diseases
• Regulatory Aspects
• World Health Organization (WHO) Prequalified Vaccines
• New Product Approvals
• Recalls
• Significant Regulatory Developments in Vaccines

Chapter 4 Market Dynamics

• Overview
• Market Drivers
• Growing Awareness of Immunization
• Growing Investments and R&D
• New Vaccines
• Prevalence of Infectious Diseases
• Market Restraints
• Vaccine Development and Pricing
• Market Opportunities
• Increased Demand from Emerging Markets
• Therapeutic Vaccines

Chapter 5 Global Market for COVID-19 Vaccines

• Overview
• COVID-19 Vaccine Technologies
• Advent of mRNA Technology
• Impact of COVID-19 on Routine Infant Vaccination
• COVID-19 Disruptions
• Stagnating Global Coverage Rate
• Progress and Challenges by Country and Region

Chapter 6 Market Breakdown by Technology

• Global Market for Vaccine Technologies by Technology
• Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
• Live-Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• Other/Combination Vaccines

Chapter 7 Market Breakdown by Disease

• Global Market for Vaccine Technologies by Disease
• Pneumococcal
• Diphtheria and Tetanus
• HPV
• MMR
• Others

Chapter 8 Market Breakdown by Age Group

• Global Market for Vaccine Technologies by Age Group Treated
• Pediatrics
• Adolescents and Adults

Chapter 9 Market Breakdown by Region

• Global Market for Vaccine Technologies by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 10 Emerging Technologies and Developments

• Developments
• mRNA Vaccines
• Viral Vector Vaccines
• Nanoparticle Vaccines
• DNA Vaccines
• Virus-Like Particle (VLP) Vaccines
• Self-Amplifying RNA Vaccines
• Innovative Adjuvants
• AI and Computational Biology
• Personalized Vaccines
• Plant-Based Vaccines

Chapter 11 Competitive Landscape

• Competitive Landscape
• Company Share Analysis

Chapter 12 Company Profiles

• ABBOTT
• ASTRAZENECA
• BAVARIAN NORDIC
• BHARAT BIOTECH INTERNATIONAL LTD.
• EMERGENT BIOSOLUTIONS INC.
• GSK PLC.
• JOHNSON & JOHNSON SERVICES INC.
• MERCK & CO. INC.
• MITSUBISHI TANABE PHARMA CORP.
• PANACEA BIOTEC LTD.
• PFIZER INC.
• SANOFI

Chapter 13 Appendix: List of Acronyms

• Acronyms

List of Tables

• Summary Table A : Global Market for Vaccine Technologies, by Vaccine Type, Through 2028
• Summary Table B : Global Market for COVID-19 Vaccines, 2019-2028
• Table 1 : History of Vaccines
• Table 2 : Types of Attenuated (Live) Vaccines
• Table 3 : Pros and Cons of Attenuated (Live) Vaccines
• Table 4 : Types of Inactivated (Killed) Vaccines
• Table 5 : Pros and Cons of Inactivated (Killed) Vaccines
• Table 6 : Types of Toxoid Vaccines
• Table 7 : Pros and Cons of Toxoid Vaccines
• Table 8 : Types of Subunit Vaccines
• Table 9 : Pros and Cons of Subunit Vaccines
• Table 10 : Types of Conjugate Vaccines
• Table 11 : Pros and Cons of Conjugate Vaccines
• Table 12 : Types of Recombinant Vector Vaccines, by Segment
• Table 13 : Pros and Cons of Recombinant Vector Vaccines
• Table 14 : Types of DNA Vaccines, by Segment
• Table 15 : Pros and Cons of DNA Vaccines
• Table 16 : Pros and Cons of RNA Vaccines
• Table 17 : Vaccine Excipient and Media Summary, Excipients included in U.S. Vaccines
• Table 18 : Vaccine-Preventable Human Viral Diseases
• Table 19 : Vaccine-Preventable Human Bacterial Diseases
• Table 20 : WHO Prequalified Vaccines, Feb. 2018-April 2020
• Table 21 : Newly Approved Vaccines, Dec. 2018-April 2020
• Table 22 : Emerging Viral Infectious Diseases, 1900-2020
• Table 23 : Global Market for COVID-19 Vaccines, 2019-2028
• Table 24 : WHO-Approved COVID-19 Vaccines: Companies and Technology Adopted
• Table 25 : COVID-19 Vaccines in the Pipeline
• Table 26 : Global Market for Vaccine Technologies, by Vaccine Type , Through 2028
• Table 27 : Global Market for Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines, by Region, Through 2028
• Table 28 : Global Market for Live-Attenuated Vaccines, by Region, Through 2028
• Table 29 : Global Market for Inactivated Vaccines, by Region, Through 2028
• Table 30 : Global Market for Toxoid Vaccines, by Region, Through 2028
• Table 31 : Global Market for Other/Combination Vaccines, by Region, Through 2028
• Table 32 : Vaccines, by Disease Type
• Table 33 : Global Market for Vaccine Technologies, by Disease Type, Through 2028
• Table 34 : Global Market for Vaccine Technologies for Pneumococcal Disease, by Region, Through 2028
• Table 35 : Global Market for Vaccine Technologies for Diphtheria and Tetanus, by Region, Through 2028
• Table 36 : Global Market for Vaccine Technologies for HPV, by Region, Through 2028
• Table 37 : Global Market for Vaccine Technologies for MMR, by Region, Through 2028
• Table 38 : Seasonal Influenza Vaccines
• Table 39 : Global Market for Vaccine Technologies for Other Disease Segments, by Region, Through 2028
• Table 40 : Global Market for Vaccine Technologies, by Age Group, Through 2028
• Table 41 : Pediatric Vaccine Doses
• Table 42 : Pediatric/VFC Vaccine Price List, 2019
• Table 43 : Influenza Vaccine Price List, 2020
• Table 44 : Global Market for Vaccine Technologies for Pediatrics, by Region, Through 2028
• Table 45 : Price List of Vaccines for Adolescents and Adults
• Table 46 : Global Market for Vaccines for Adolescents and Adults, by Region, Through 2028
• Table 47 : Global Market for Vaccine Technologies, by Region, Through 2028
• Table 48 : North American Market for Vaccine Technologies, by Vaccine Type, Through 2028
• Table 49 : North American Market for Vaccine Technologies, by Country, Through 2028
• Table 50 : Immunization Schedule, Canada, 2020
• Table 51 : European Market for Vaccine Technologies, by Vaccine Type, Through 2028
• Table 52 : European Market for Vaccine Technologies, by Country, Through 2028
• Table 53 : Immunization Schedule, Germany, 2020
• Table 54 : Immunization Schedule, France, 2020
• Table 55 : Vaccination and Immunization Schedule, U.K., 2020
• Table 56 : Immunization Schedule, Italy, 2020
• Table 57 : Asia-Pacific Market for Vaccine Technologies, by Vaccine Type, Through 2028
• Table 58 : Asia-Pacific Market for Vaccine Technologies, by Country, Through 2028
• Table 59 : Immunization Schedule, China, 2020
• Table 60 : Immunization Schedule, Japan, 2020
• Table 61 : Immunization Schedule, India, 2020
• Table 62 : GAVI Support to India, 2001-2021
• Table 63 : Vaccination Coverage Estimates, Middle East and North Africa, 2014-2020
• Table 64 : Vaccination Coverage, Latin America, and Caribbean, 2014-2020
• Table 65 : RoW Market for Vaccine Technologies, by Vaccine Type, Through 2028
• Table 66 : RoW Market for Vaccine Technologies, by Sub-Region, Through 2028
• Table 67 : Abbott: Company Snapshot
• Table 68 : Abbott Laboratories: Financial Performance, 2022
• Table 69 : Astrazeneca: Company Snapshot
• Table 70 : AstraZeneca: Vaccines
• Table 71 : AstraZeneca: Recent Developments, 2021
• Table 72 : Bavarian Nordic: Company Snapshot
• Table 73 : Bavarian Nordic: Recent Developments, 2021
• Table 74 : Bharat Biotech: Company Snapshot
• Table 75 : Bharat Biotech: Vaccines
• Table 76 : Bharat Biotech: Recent Developments, 2020 and 2021
• Table 77 : Emergent BioSolutions: Company Snapshot
• Table 78 : Emergent BioSolutions: Vaccines
• Table 79 : Emergent BioSolutions: Recent Developments, 2020 and 2021
• Table 80 : GSK Plc: Company Snapshot
• Table 81 : GSK Plc: Vaccines Offered
• Table 82 : GSK Plc.: Recent Developments, 2020 and 2021
• Table 83 : Johnson & Johnson: Company Snapshot
• Table 84 : Johnson & Johnson: Recent Developments, 2021
• Table 85 : Merck & Co. Inc.: Company Snapshot
• Table 86 : Merck & Co. Inc.: Vaccines
• Table 87 : Merck & Co. Inc.: Recent Developments, 2020 and 2021
• Table 88 : Mitsubishi Tanabe Pharma Corp.: Company Snapshot
• Table 89 : Panacea Biotec Ltd.: Company Snapshot
• Table 90 : Pfizer Inc.: Company Snapshot
• Table 91 : Pfizer Inc.: Recent Developments, 2020 and 2021
• Table 92 : Sanofi: Company Snapshot
• Table 93 : Sanofi: Vaccines
• Table 94 : Sanofi: Recent Developments, 2021
• Table 95 : Acronyms Used in This Report

List of Figures

• Summary Figure A : Global Market for Vaccine Technologies, by Vaccine Type, 2022-2028
• Summary Figure B : Global Market for COVID-19 Vaccines, 2019-2028
• Figure 1 : Global Markets for Vaccine Technologies Market Dynamics
• Figure 2 : Global Market Share of COVID-19 Vaccines, by Technology, 2022
• Figure 3 : Global Market Share for Vaccine Technologies, by Vaccine Type, 2022
• Figure 4 : Global Market for Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines, 2020-2028
• Figure 5 : Global Market for Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, by Region, 2020-2028
• Figure 6 : Global Market for Live-Attenuated Vaccines, 2020-2028
• Figure 7 : Global Market for Live-Attenuated Vaccines, by Region, 2020-2028
• Figure 8 : Global Market for Inactivated Vaccines, 2020-2028
• Figure 9 : Global Market for Inactivated Vaccines, by Region, 2020-2028
• Figure 10 : Global Market for Toxoid Vaccines, 2020-2028
• Figure 11 : Global Market for Toxoid Vaccines, by Region, 2020-2028
• Figure 12 : Global Market for Other/Combination Vaccines, 2020-2028
• Figure 13 : Global Market for Other/Combination Vaccines, by Region, 2020-2028
• Figure 14 : Global Market Share of Vaccine Technologies, by Disease Type, 2022
• Figure 15 : Global Market for Vaccine Technologies for Pneumococcal Disease, 2020-2028
• Figure 16 : Global Market for Vaccine Technologies for Pneumococcal Disease, by Region, 2020-2028
• Figure 17 : Global Market for Vaccine Technologies for Diphtheria and Tetanus, 2020-2028
• Figure 18 : Global Market for Vaccine Technologies for Diphtheria and Tetanus, by Region, 2020-2028
• Figure 19 : Global Market for Vaccine Technologies for HPV, 2020-2028
• Figure 20 : Global Market for Vaccine Technologies for HPV, by Region, 2020-2028
• Figure 21 : Global Market for Vaccine Technologies for MMR, 2020-2028
• Figure 22 : Global Market for Vaccine Technologies for MMR, by Region, 2020-2028
• Figure 23 : Global Market for Vaccine Technologies for Other Disease Segments, 2020-2028
• Figure 24 : Global Market for Vaccine Technologies for Other Disease Segments, by Region, 2020-2028
• Figure 25 : Global Market Share of Vaccine Technologies, by Age Group, 2022
• Figure 26 : Global Market for Vaccine Technologies for Pediatrics, 2020-2028
• Figure 27 : Global Market for Vaccine Technologies for Pediatrics, by Region, 2020-2028
• Figure 28 : Global Market for Vaccines for Adolescents and Adults, 2020-2028
• Figure 29 : Global Market for Vaccines for Adolescents and Adults, by Region, 2020-2028
• Figure 30 : Global Market for Vaccine Technologies, by Region, 2020-2028
• Figure 31 : Global Market Share of Vaccine Technologies, by Region, 2022
• Figure 32 : North American Market Share for Vaccine Technologies, by Vaccine Type, 2022
• Figure 33 : North American Market Share for Vaccine Technologies, by Country, 2022
• Figure 34 : U.S. Market for Vaccine Technologies, 2020-2028
• Figure 35 : Canadian Market for Vaccine Technologies, 2020-2028
• Figure 36 : European Market Share for Vaccine Technologies, by Vaccine Type, 2022
• Figure 37 : European Market Share for Vaccine Technologies, by Country, 2022
• Figure 38 : German Market for Vaccine Technologies, 2020-2028
• Figure 39 : Russian Market for Vaccine Technologies, 2020-2028
• Figure 40 : French Market for Vaccine Technologies, 2020-2028
• Figure 41 : U.K. Market for Vaccine Technologies, 2020-2028
• Figure 42 : Italian Market for Vaccine Technologies, 2020-2028
• Figure 43 : Spanish Market for Vaccine Technologies, 2020-2028
• Figure 44 : Rest of the European Market for Vaccine Technologies, 2020-2028
• Figure 45 : Asia-Pacific Market Share for Vaccine Technologies, by Vaccine Type, 2022
• Figure 46 : Asia-Pacific Market Share for Vaccine Technologies, by Country, 2022
• Figure 47 : Chinese Market for Vaccine Technologies, 2020-2028
• Figure 48 : RoW Market Share for Vaccine Technologies, by Vaccine Type, 2022
• Figure 49 : RoW Market Share for Vaccine Technologies, by Sub-Region, 2022
• Figure 50 : Global Market Share for Vaccine Technologies, by Company, 2022
• Figure 51 : Abbott Laboratories: Financial Performance, 2021 and 2022
• Figure 52 : Abbott Laboratories: Revenue Share, by Business Unit, 2022
• Figure 53 : Abbott Laboratories: Revenue Share, by County/Region, 2022
• Figure 54 : AstraZeneca: Net Revenue, 2016-2020
• Figure 55 : AstraZeneca: Revenue Share, by Business Segment, 2020
• Figure 56 : AstraZeneca: Revenue Share, by Region/Country, 2020
• Figure 57 : Bavarian Nordic: Net Revenue, 2016-2020
• Figure 58 : Bavarian Nordic: Revenue Share, by Country, 2020
• Figure 59 : Emergent BioSolutions: Net Revenue, 2016-2020
• Figure 60 : GSK Plc: Net Revenue, 2016-2020
• Figure 61 : GSK Plc: Revenue Share, by Business Segment, 2020
• Figure 62 : GSK Plc: Revenue Share, by Region, 2020
• Figure 63 : Johnson & Johnson: Net Revenue, 2016-2020
• Figure 64 : Johnson & Johnson: Revenue Share, by Business Segment, 2020
• Figure 65 : Johnson & Johnson: Revenue Share, by Country/Region, 2020
• Figure 66 : Merck & Co. Inc.: Net Revenue, 2016-2020
• Figure 67 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2020
• Figure 68 : Merck & Co. Inc.: Revenue Share, by Region/Country, 2021
• Figure 69 : Panacea Biotec Ltd.: Net Revenue, 2018-2022
• Figure 70 : Panacea Biotec Ltd.: Revenue Share, by Business Segment, 2022
• Figure 71 : Panacea Biotec Ltd.: Revenue Share, by Country/Region, 2022
• Figure 72 : Pfizer Inc.: Net Revenue, 2020-2022
• Figure 73 : Pfizer Inc.: Revenue Share, by Region/Country, 2022
• Figure 74 : Sanofi: Net Revenue, 2017-2021
• Figure 75 : Sanofi: Revenue Share, by Business Segment, 2020
• Figure 76 : Sanofi: Revenue Share, by Region, 2021